Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs mycophenolate mofetil in moderate-to-severe pemphigus vulgaris
2014-000382-41Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) comparing Rituximab arm with Mycophenolate mofetil arm (2 arms). Primary endpoint: Sustained complete remission at Week 52 (PDAI-based). Started Dec 2014; status: completed.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2014-000382-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000382-41.